Cargando…
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, inclu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071222/ https://www.ncbi.nlm.nih.gov/pubmed/29932105 http://dx.doi.org/10.3390/cancers10070211 |
_version_ | 1783343834596376576 |
---|---|
author | Isidori, Alessandro Loscocco, Federica Ciciarello, Marilena Corradi, Giulia Lecciso, Mariangela Ocadlikova, Darina Parisi, Sarah Salvestrini, Valentina Amadori, Sergio Visani, Giuseppe Curti, Antonio |
author_facet | Isidori, Alessandro Loscocco, Federica Ciciarello, Marilena Corradi, Giulia Lecciso, Mariangela Ocadlikova, Darina Parisi, Sarah Salvestrini, Valentina Amadori, Sergio Visani, Giuseppe Curti, Antonio |
author_sort | Isidori, Alessandro |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes. |
format | Online Article Text |
id | pubmed-6071222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60712222018-08-09 Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach Isidori, Alessandro Loscocco, Federica Ciciarello, Marilena Corradi, Giulia Lecciso, Mariangela Ocadlikova, Darina Parisi, Sarah Salvestrini, Valentina Amadori, Sergio Visani, Giuseppe Curti, Antonio Cancers (Basel) Review Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes. MDPI 2018-06-22 /pmc/articles/PMC6071222/ /pubmed/29932105 http://dx.doi.org/10.3390/cancers10070211 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Isidori, Alessandro Loscocco, Federica Ciciarello, Marilena Corradi, Giulia Lecciso, Mariangela Ocadlikova, Darina Parisi, Sarah Salvestrini, Valentina Amadori, Sergio Visani, Giuseppe Curti, Antonio Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
title | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
title_full | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
title_fullStr | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
title_full_unstemmed | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
title_short | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
title_sort | immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: time for a biology-driven approach |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071222/ https://www.ncbi.nlm.nih.gov/pubmed/29932105 http://dx.doi.org/10.3390/cancers10070211 |
work_keys_str_mv | AT isidorialessandro immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT loscoccofederica immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT ciciarellomarilena immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT corradigiulia immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT leccisomariangela immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT ocadlikovadarina immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT parisisarah immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT salvestrinivalentina immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT amadorisergio immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT visanigiuseppe immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT curtiantonio immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach |